Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UU Scientists Developing Breakthrough Diabetes Drugs

07.10.2005


University of Ulster scientists are developing innovative drugs that could represent important new therapeutic tools to help ease the burden of diabetes worldwide. The news comes as a UN World Health Organisation report identifies diabetes as one of the major health issues facing the world in the 21st century.



The research team at UU have discovered that modified-forms of GIP, a naturally occurring molecule produced by the body, can combat key symptoms of diabetes. This stimulated the formation of a new company to develop production of new anti-diabetic agents.

Current statistics report some 150 million diagnosed cases of diabetes worldwide, and that figure is set to double within 20 years, according Dr Neville McClenaghan, a prime mover in the new company Diabetica Limited.


“The holy grail of diabetes treatment is safe and effective management of blood glucose. We believe that novel molecules arising from our platform GIP technology should provide effective new tools to help individuals better control the condition known as Type 2 diabetes,” he said.

“That’s really what physicians are looking for at the minute - new drugs that offer improvements or enhancement over current drugs.”

Diabetes is a complex metabolic disorder clinically defined by high blood glucose levels resulting from a relative or absolute absence of insulin-production coupled with defective insulin action in body tissues. The latter is a defining characteristic of the ‘metabolic syndrome’ and is an important link between Type 2 diabetes and other conditions including obesity, heart disease and stroke.

In diabetes there is a breakdown in the person’s ability to regulate blood-glucose levels, and thus pharmacological treatments are required to bring the blood glucose levels back down to safe levels.

The main pharmacological approaches to the treatment of diabetes are focussed on replacing insulin by injection or the use of drugs, which either increase circulating insulin or enhance its action on insulin-sensitive tissues.

“Diabetes and the related conditions, metabolic syndrome and obesity, are reaching epidemic proportions and thus are major healthcare challenges. This clearly prompts the development of new and innovative approaches for effective management and treatment of this complex disease” said Dr McClenaghan.

Years of research by the team at UU have culminated in two distinct therapeutic products developed from the gut peptide, GIP, which is released into the blood following eating. Preclinical studies have revealed that both therapeutic products exhibit potent glucose-lowering actions mediated by either increasing circulating insulin or enhancing insulin action.

“We have discovered that strategic bio-engineering of the GIP molecule can generate stable long-acting forms with two principal modes of anti-diabetic action and have patent-protected the technology,” he said.

“Diabetica’s therapeutic GIP products have generated a lot of interest. GIP-based therapies are exciting new approaches which offer considerable advantages over existing and emerging diabetes/obesity therapies, which suffer from shortcomings such as poor efficacy, difficult dosing regimens and adverse side effects. This is a very exciting time for Diabetica as our two novel GIP drugs - Incretide and Metalog - could provide a major advance in the effective management of diabetes, metabolic syndrome and obesity.”

The co-founders of Diabetica Limited - Professor Peter Flatt, Professor Finbarr O’Harte and Dr Neville McClenaghan - established the Coleraine-based biotechnology company last year as a first step to achieving a sound commercial footing for product development.

In June, the University’s technology transfer arm, UUTech Limited and Seroba BioVentures Limited, a life sciences venture capital fund, announced that they would provide funding for Diabetica’s pre-clinical testing programmes.

Dr McClenaghan said: “We now wish to take our GIP drugs through formal clinical evaluation. Clinical trials are a vital step along the way to full approval and prescribed use of any drug. Diabetica’s GIP drugs, Incretide and Metalog, are two distinctly different products addressing the major unmet need for “smart therapeutics” whose actions are regulated by circulating levels of blood glucose. Thus, we anticipate that Incretide and Metalog will offer the individual immediate advantages associated with better control of blood glucose levels and reducing the likelihood of development of complications associated with long-term hyperglycaemia.”

The increasing global incidence of diabetes has led to major investments by the bio-pharmaceutical industry to develop and acquire therapeutic, drug delivery and diagnostic solutions for diabetes and obesity, creating significant opportunities for Diabetica’s novel therapeutics as the anti-diabetic and anti-obesity drugs of tomorrow.

Brian O’Connor, Chairman of UUTech said: “UUTech is pleased at the progress made so far and will work to ensure that Diabetica has the best possible chance of success during the development phase of this exciting science over the next several years."

“We are delighted with the validation this funding gives to our technology,” said Matt O’Driscoll, Chief Executive Officer of Diabetica. “This is the first stage in a fundraising and corporate partnering campaign over the next 12 months designed to push the development of our lead GIP molecules into the clinic.”

David Young | alfa
Further information:
http://www.ulster.ac.uk
http://www.ulster.ac.uk/news/releases/2005/1860.html

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Northern oceans pumped CO2 into the atmosphere

27.03.2017 | Earth Sciences

Fingerprint' technique spots frog populations at risk from pollution

27.03.2017 | Life Sciences

Big data approach to predict protein structure

27.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>